Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan
- 7 May 2022
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (8) , 6775-6783
Abstract
Purpose The dose-limiting factor of ramucirumab plus docetaxel (RAM + DTX) in patients with non-small cell lung cancer (NSCLC) is febrile neutropenia (FN), which has a high incidence in Asians. This study aimed to evaluate the cost-effectiveness of pegfilgrastim (Peg-G) in patients with NSCLC receiving RAM + DTX in Japan. Methods We simulated model patients treated with RAM + DTX in Japan and developed a decision-analytical model for patients receiving Peg-G prophylaxis or no primary prophylaxis. The expected cost, quality-adjusted life-year (QALY), and incremental cost-effectiveness ratio (ICER) of each treatment were calculated from the perspective of a Japanese healthcare payer. The willingness-to-pay (WTP) threshold was set at 45,867 United States dollars (USD) (5 million Japanese yen) per QALY gained. The probabilities, utility values, and other costs were obtained from published sources. Deterministic sensitivity analysis (DSA) and probabilistic analysis were conducted to evaluate the effect of each parameter and robustness of the base-case results. Results The expected cost and QALYs were 20,275 USD and 0.701 for Peg-G prophylaxis and 17,493 USD and 0.672 for no primary prophylaxis, respectively. The ICER was calculated to be 97,519 USD per QALY gained. The results were most sensitive to FN risk with Peg-G. When FN risk with no primary prophylaxis exceeded 51% or the cost of Peg-G was less than 649 USD per injection, the ICER was below the WTP threshold. The probabilistic analysis revealed a 9.1% probability that the ICER was below the WTP threshold. Conclusion Peg-G is not cost-effective in patients with NSCLC receiving RAM + DTX in Japan.Keywords
All Related Versions
This publication has 35 references indexed in Scilit:
- Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analysesJournal of Medical Economics, 2013
- Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis Against Febrile Neutropenia in Lymphoma PatientsJNCI: Journal of the National Cancer Institute, 2013
- Risk and Healthcare Costs of Chemotherapy-Induced Neutropenic Complications in Women with Metastatic Breast CancerChemotherapy, 2012
- Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisBMC Cancer, 2011
- International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?Health Economics, 2009
- Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United StatesCurrent Medical Research and Opinion, 2008
- Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY thresholdExpert Review of Pharmacoeconomics & Outcomes Research, 2008
- Health state utilities for non small cell lung cancerHealth and Quality of Life Outcomes, 2008
- Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic ReviewJournal of Clinical Oncology, 2007
- Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled TrialsJournal of Clinical Oncology, 2005